Refinements in procedures of pancreas enzymatic digestion, and new immunosuppression strategies have allowed clinical trials of islet transplantation in patients with Type I (insulin-dependent) diabetes mellitus [1]. Until recently, the majority of transplants were done in patients who also receive kidney allografts [2]. Clinical results in these patients have not been satisfactory, with a 12 month survival of islet allografts (as defined by basal C-peptide > 0.17 nmol/l) being achieved in less than 40 % of recipients, and insulin independence in only 13 % of recipients [2]. The number of recipients who become insulin independent after transplantation is low and so the procedure has also been considered successful when recipients maintained detectable serum C-peptide during follow-up [3±4] or HbA 1 c was normalized [5]. Regardless of which outcome measure is used, around 30 % of the cases reported in the International Registry of Transplantation (ITR) showed the absence of islet function af- Diabetologia (2002) Abstract Aims/hypothesis. Islet transplantation is a minimally invasive approach to curing Type I (insulin-dependent) diabetes mellitus. Success has recently been reported in patients receiving solitary islet transplants but the outcome in patients receiving islets together with, or after, kidney transplants has been limited and unpredictable. Methods. Here we report successful islet transplantation in a cohort of 15 patients with Type I diabetes who were followed for at least 1 year after islet transplantation, after having already received kidney allografts because of end-stage nephropathy. Results. C-peptide after transplantation was higher than 0.17 nmol/l in all 15 recipients, reflecting the absence of primary non-function. Insulin requirement was reduced by over 50 % in all but one patient, and insulin independence was achieved in 10 (66 %) recipients, five of whom now have stable, prolonged insulin independence, well controlled fasting glycaemia, a substantial first-phase and normal secondphase response to glucose, normal insulin sensitivity (HOMA analyses) and HbA 1 c of under 6.2 % (33, 26, 18, 13 and 12 months after transplantation respectively). Of importance for patient management, an assessment of fasting blood glucose and proinsulin values following overnight withdrawal of insulin administration one month after transplantation was a potent predictor of insulin independence, and could be used to decide patients who should have further islet preparations. Conclusion/interpretation. These findings support the use of islet transplantation as a cure for Type I diabetes in patients with severe complications. [Diabetologia (2002) 45: 77±84]